BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/21/2019 3:42:23 AM | Browse: 869 | Download: 1060
 |
Received |
|
2019-03-07 02:10 |
|
Peer-Review Started |
|
2019-03-07 06:28 |
|
To Make the First Decision |
|
2019-04-08 00:43 |
|
Return for Revision |
|
2019-04-08 07:02 |
|
Revised |
|
2019-04-17 13:42 |
|
Second Decision |
|
2019-04-28 09:33 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2019-04-29 10:17 |
|
Articles in Press |
|
2019-04-29 10:17 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2019-05-04 22:56 |
|
Typeset the Manuscript |
|
2019-06-19 05:46 |
|
Publish the Manuscript Online |
|
2019-06-21 03:42 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Field of Vision |
| Article Title |
Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Feng Yang, Chen Jin, De-Liang Fu and Andrew L Warshaw |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Key R&D Program of China |
2017YFC1308604 |
|
| Corresponding Author |
Feng Yang, MD, PhD, Associate Professor, Surgeon, Surgical Oncologist, Department of Pancreatic Surgery, Pancreatic Disease Institute, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Central Urumqi Road, Shanghai 200040, China. yffudan98@126.com |
| Key Words |
Pancreatic cancer; Adjuvant therapy; FOLFIRINOX; Neutrophil-to-lymphocyte; Nanoliposomal irinotecan |
| Core Tip |
Adjuvant chemotherapy for pancreatic cancer has been developed based on the experiences made with palliative chemotherapy. Nevertheless, the optimal regimen remains controversial. The Partenariat de Recherche en Oncologie Digestive 24 trial showed an impressive benefit of modified FOLFIRINOX over gemcitabine alone. The remarkable results mark a new milestone in treating resectable pancreatic cancer and have now changed the standard of care. Here, we discussed an issue of difference between this trial and previous phase III trials, as well as potential biomarkers predicting therapeutic response. Several ongoing trials of replacing part of the FOLFIRINOX regimen with other drugs for pancreatic cancer were summarized. |
| Publish Date |
2019-06-21 03:42 |
| Citation |
Yang F, Jin C, Fu DL, Warshaw AL. Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges. World J Gastroenterol 2019; 25(23): 2839-2845 |
| URL |
https://www.wjgnet.com/1007-9327/full/v25/i23/2839.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v25.i23.2839 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
